Stealth Peptides Target Cellular Powerhouses to Fight Rare and Common Age-Related Diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical mechanisms and animal disease models.
PubMed 30381054 · doi:10.2174/0929866525666181101105209
What was done
This narrative review summarizes the mechanism of action and preclinical evidence for cell-permeable Szeto-Schiller (SS) peptides that selectively target cardiolipin on the inner mitochondrial membrane.
What was found
The abstract reports no numerical data. It notes that SS peptides promote electron transport chain efficiency to increase ATP production, mitigate reactive oxygen species generation, repair damaged mitochondria, and suppress downstream inflammatory cascades and tissue remodeling in preclinical disease models.
Why it matters
It highlights a class of mitochondria-targeted peptides designed to treat the cellular bioenergetic failure underlying both rare disorders and common age-related degenerative diseases.
Limits
The abstract references only preclinical disease models and presents no human clinical data. No quantitative effect sizes, sample sizes, or specific study methods are reported.
Cited by
- supports The peptide SS-31 was discovered by Hazel Szeto.